Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC

The introduction of immune checkpoint inhibitors (ICIs) in non-oncogene addicted non-small cell lung cancer (NSCLC) has revolutionized the treatment scenario and led to a meaningful improvement in patient prognosis. Disappointingly, the success of ICI therapy in NSCLC has not been fully replicated i...

Descripción completa

Detalles Bibliográficos
Autores principales: Cantini, Luca, Pecci, Federica, Merloni, Filippo, Lanese, Andrea, Lenci, Edoardo, Paoloni, Francesco, Aerts, Joachim G.J.V., Berardi, Rossana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400728/
https://www.ncbi.nlm.nih.gov/pubmed/36046087
http://dx.doi.org/10.37349/etat.2021.00030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400728/
https://www.ncbi.nlm.nih.gov/pubmed/36046087
http://dx.doi.org/10.37349/etat.2021.00030

Ejemplares similares